Shalom Haggiag - Concepedia

Author

Shalom Haggiag

Carlo Forlanini Hospital ORCID

Also Known As

S. Haggiag, Shalom Haggiag

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

Carlo Forlanini Hospital Sapienza University of Rome Ospedale San Filippo Neri Istituti di Ricovero e Cura a Carattere Scientifico Agostino Gemelli University Polyclinic

About

Shalom Haggiag is an author at Carlo Forlanini Hospital specializing in medicine, neuroimmunology, and neurology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	334
2	Social Sciences	2	2	79
3	Public Health	1	1	30
4	Cell Biology	1	1	34
5	Cellular Physiology	1	1	34

Shalom Haggiag

Publications

Citations

H-Index

Page 1

	Year	Citations
The “Gender Factor” in Wearing‐Off among Patients with Parkinson’s Disease: A Post Hoc Analysis of DEEP Study Delia Colombo, Giovanni Abbruzzese, Angelo Antonini, The Scientific World JOURNAL	2015	86
Shift of multiple sclerosis onset towards older age Luca Prosperini, Matteo Lucchini, Serena Ruggieri, Journal of Neurology Neurosurgery & Psychiatry	2022	68
Induction Versus Escalation in Multiple Sclerosis: A 10-Year Real World Study Luca Prosperini, Chiara Mancinelli, Claudio Solaro, Neurotherapeutics Disease ProgressionNeurological DisorderMedicineNeurologyNeuroscience	2020	66
Increased post-traumatic survival of neurons in IL-6-knockout mice on a background of EAE susceptibility Jasmin Fisher, Tal Mizrahi, Hadas Schori, Journal of Neuroimmunology InflammationNeuroregenerationIl-6-knockout MicePost-traumatic SurvivalMedicine	2001	59
Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis Luca Prosperini, Serena Ruggieri, Shalom Haggiag, Neurology Neuroimmunology & Neuroinflammation	2021	57
Age-related adverse events of disease-modifying treatments for multiple sclerosis: A meta-regression Luca Prosperini, Shalom Haggiag, Carla Tortorella, Multiple Sclerosis Journal	2020	56
Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis Luca Prosperini, Francesco Saccà, Cinzia Cordioli, Journal of Neurology Real-world EffectivenessMedicineTreatment-naïve PatientsTreatment OptionPharmacotherapy	2016	54
Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis Luca Prosperini, Chiara Mancinelli, Shalom Haggiag, Journal of Neurology Neurosurgery & Psychiatry	2020	46
Fingolimod vs dimethyl fumarate in multiple sclerosis Luca Prosperini, Matteo Lucchini, Shalom Haggiag, Neurology	2018	44
Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study Massimiliano Mirabella, Luca Prosperini, Matteo Lucchini, CNS Drugs Drug SafetyNeurological DisorderMedicinePharmacotherapyNeurology	2018	37

Page 1